Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 20/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29382074 | 1.00 | KDM1A (0.50) | KDM1A | |
| SCHEMBL17403589 | 0.87 | KDM1A (0.46) | KDM1A | |
| SCHEMBL18150653 | 0.83 | KDM1A (0.51) | KDM1A | |
| SCHEMBL21170725 | 0.81 | KDM1A (0.32) | KDM1A | |
| SCHEMBL18842800 | 0.80 | KDM1A (0.51) | KDM1A | |
| SCHEMBL20129759 | 0.79 | HRH3 (0.43) | KDM1A | |
| SCHEMBL18842802 | 0.79 | KDM1A (0.55) | KDM1A | |
| SCHEMBL18849117 | 0.78 | KDM1A (0.49) | KDM1A | |
| SCHEMBL18842798 | 0.77 | KDM1A (0.45) | KDM1A | |
| SCHEMBL17403633 | 0.77 | KDM1A (0.57) | KDM1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3511319-B1 | INHIBITORS OF LYSINE SPECIFIC DEMETHYLASE-1 | CELGENE QUANTICEL RES INC (US) | 2023-05-03 | — | — | EP | claimed |
| EP-3511319-B1 | INHIBITORS OF LYSINE SPECIFIC DEMETHYLASE-1 | CELGENE QUANTICEL RES INC (US) | 2023-05-03 | — | — | EP | disclosed |
| EP-3511319-B1 | INHIBITORS OF LYSINE SPECIFIC DEMETHYLASE-1 | CELGENE QUANTICEL RES INC (US) | 2023-05-03 | — | — | EP | disclosed |
| EP-3164380-B1 | INHIBITORS OF LYSINE SPECIFIC DEMETHYLASE-1 | CELGENE QUANTICEL RES INC (US) | 2022-02-09 | — | — | EP | disclosed |
| EP-3164380-B1 | INHIBITORS OF LYSINE SPECIFIC DEMETHYLASE-1 | CELGENE QUANTICEL RES INC (US) | 2022-02-09 | — | — | EP | disclosed |
| CN-108530424-B | Inhibitors of lysine-specific demethylase-1 | 赛尔基因昆蒂赛尔研究公司 | 2021-10-01 | — | — | CN | disclosed |
| EP-3511319-A1 | INHIBITORS OF LYSINE SPECIFIC DEMETHYLASE-1 | Celgene Quanticel Research, Inc. (US) | 2019-07-17 | — | — | EP | disclosed |
| EP-3511319-A1 | INHIBITORS OF LYSINE SPECIFIC DEMETHYLASE-1 | Celgene Quanticel Research, Inc. (US) | 2019-07-17 | — | — | EP | disclosed |
| US-20190002456-A1 | INHIBITORS OF LYSINE SPECIFIC DEMETHYLASE-1 | CELGENE QUANTICEL RES INC (US) | 2019-01-03 | — | — | US | disclosed |
| US-20190002456-A1 | INHIBITORS OF LYSINE SPECIFIC DEMETHYLASE-1 | CELGENE QUANTICEL RES INC (US) | 2019-01-03 | — | — | US | disclosed |
| US-20180127408-A1 | INHIBITORS OF LYSINE SPECIFIC DEMETHYLASE-1 | CELGENE QUANTICEL RES INC (US) | 2018-05-10 | — | — | US | disclosed |
| US-9902719-B2 | Inhibitors of lysine specific demethylase-1 | CELGENE QUANTICEL RESEARCH, INC. (US) | 2018-02-27 | — | — | US | disclosed |
| US-9902719-B2 | Inhibitors of lysine specific demethylase-1 | CELGENE QUANTICEL RESEARCH, INC. (US) | 2018-02-27 | — | — | US | disclosed |
| US-9902719-B2 | Inhibitors of lysine specific demethylase-1 | CELGENE QUANTICEL RESEARCH, INC. (US) | 2018-02-27 | — | — | US | disclosed |
| US-20170129882-A1 | INHIBITORS OF LYSINE SPECIFIC DEMETHYLASE-1 | CELGENE QUANTICEL RESEARCH, INC. (US) | 2017-05-11 | — | — | US | disclosed |
| US-20170129882-A1 | INHIBITORS OF LYSINE SPECIFIC DEMETHYLASE-1 | CELGENE QUANTICEL RESEARCH, INC. (US) | 2017-05-11 | — | — | US | disclosed |
| US-20170129882-A1 | INHIBITORS OF LYSINE SPECIFIC DEMETHYLASE-1 | CELGENE QUANTICEL RESEARCH, INC. (US) | 2017-05-11 | — | — | US | disclosed |
| EP-3164380-A1 | INHIBITORS OF LYSINE SPECIFIC DEMETHYLASE-1 | Celgene Quanticel Research, Inc. (US) | 2017-05-10 | — | — | EP | disclosed |
| WO-2016003917-A1 | INHIBITORS OF LYSINE SPECIFIC DEMETHYLASE-1 | Quanticel Pharmaceuticals, Inc. (US) | 2016-01-07 | — | — | WO | disclosed |
| WO-2016003917-A1 | INHIBITORS OF LYSINE SPECIFIC DEMETHYLASE-1 | Quanticel Pharmaceuticals, Inc. (US) | 2016-01-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170129882-A1 | INHIBITORS OF LYSINE SPECIFIC DEMETHYLASE-1 | KDM1B, KDM1A, KDM3A | KDM1A 2/4885 |
| US-20180127408-A1 | INHIBITORS OF LYSINE SPECIFIC DEMETHYLASE-1 | KDM1B, KDM1A, KDM3A | KDM1A 2/4885 |
| US-20190002456-A1 | INHIBITORS OF LYSINE SPECIFIC DEMETHYLASE-1 | KDM1B, KDM1A, KDM3A | KDM1A 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.